What is the recommended activated clotting time (ACT) value for safe removal of a vascular sheath?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Recommended ACT Value for Vascular Sheath Removal

For safe removal of arterial sheaths after percutaneous coronary intervention, target an ACT < 160 seconds, though sheaths can be safely removed at ACT values up to 250 seconds depending on sheath size and patient factors.

Evidence-Based Thresholds

The most recent ACC/AHA/SCAI guidelines 1 establish target ACT ranges of 250-300 seconds during PCI when using unfractionated heparin (UFH), but do not specify exact removal thresholds. However, research evidence provides practical guidance:

Primary Recommendation

  • ACT < 160 seconds is the most commonly validated threshold for routine sheath removal 2
  • At 3 hours post-heparin, only 21% of patients achieve ACT < 160 seconds, making this a practical and safe target 2

Alternative Approach

  • ACT < 150 seconds represents a more conservative threshold, though only 7% of patients reach this level at 3 hours post-heparin 2
  • Recent evidence suggests routine ACT monitoring may not be necessary for peripheral vascular sheaths, as outcomes were equivalent whether sheaths were removed with or without ACT guidance 3

Practical Algorithm for Sheath Removal

Timing:

  • Begin checking ACT levels 3 hours after the last heparin dose 2
  • This timing optimizes efficiency while maintaining safety

Sheath Size Considerations:

  • ≤ 8.5 Fr sheaths: Can be removed without specific ACT requirements even with elevated coagulation parameters 4
  • > 8.5 Fr sheaths: Consider correcting coagulopathy if PT ≥ 18s or INR ≥ 1.5 4

Platelet Requirements:

  • Minimum platelet count of ≥ 10 × 10⁹/L for routine sheath removal 4

Critical Caveats

Device Variability

ACT measurements vary significantly between platforms 5. Mean differences of 50-60 seconds (15-25% discrepancy) exist between devices:

  • Hemochron devices: Read approximately 50 seconds higher than other platforms
  • i-STAT (Abbott): Tends to read lower
  • Medtronic ACT Plus: Intermediate values

If your institution uses Hemochron devices, the target ACT for removal should be adjusted upward by approximately 50 seconds from the standard 160-second threshold 1, 5.

Sampling Location Matters

Blood drawn from the guiding catheter reads 43 seconds higher on average than blood from the arterial sheath 6. In 30% of patients, catheter samples showed therapeutic ACT while sheath samples were subtherapeutic 6. Always sample from the arterial access sheath when determining readiness for removal.

Patient-Specific Factors

  • Smokers may require higher UFH doses to achieve therapeutic ACT during procedures, though this doesn't directly affect removal thresholds 7
  • Female patients have higher transfusion risk despite lower bleeding risk 8
  • Longer CPB times correlate with increased bleeding risk 8

Cost-Effectiveness Consideration

Implementing a protocol of checking ACT at 3 hours post-heparin and removing sheaths at ACT < 160 seconds can save approximately $5,000 in nursing time per institution by reducing unnecessary repeat measurements 2.

Related Questions

After percutaneous transluminal coronary angioplasty (PTCA), at what activated clotting time (ACT) should the radial sheath and femoral sheath be removed?
What is the activated clotting time (ACT) protocol for anticoagulation during percutaneous coronary interventions, including heparin dosing, target ACT range, monitoring, and alternative agents?
What is the recommended intra‑procedural unfractionated heparin dosing and activated clotting time target for pulmonary vein isolation, how should chronic oral anticoagulation be managed before and after the ablation, and what are the alternatives for patients with heparin‑induced thrombocytopenia?
As a patient‑physician who has been smoke‑free for 1.5 years, has a BMI of 22.5, and a repeat coronary angiography one year after angioplasty showing no new changes, what measures can I take to further reduce my risk of major adverse cardiovascular events and maintain a healthy life?
What activated partial thromboplastin time (aPTT) is considered acceptable for removal of a vascular sheath?
Can you write a realistic patient round with the provider for the following patients: 1) 57-year-old female with CVA and type 2 diabetes, Shiley 8 trach on a cool trach collar at 28% FiO2; 2) 68-year-old female with COPD, Shiley 8 trach on ventilator CMV mode 14/450/+5/40%, weaned to cool trach collar at 40% FiO2, receiving DuoNeb and budesonide; 3) 81-year-old female post‑stroke, Shiley 6XLT trach with proximal cuff on ventilator SIMV mode 12/380/15/+5/40%, atrial fibrillation; 4) 59-year-old female with CVA, recent capping, nasal cannula 2 L; 5) 75-year-old male with dysphagia, Shiley 8 trach on ventilator CMV mode 14/450/+5/30%, receiving DuoNeb; 6) 57-year-old female with ICH and ESRD, Shiley 4 trach, CPAP at night and cool trach collar day; 7) 58-year-old male with ICH, Shiley 5 trach, frequently removes trach collar; 8) 31-year-old male with cerebral palsy, Shiley 7 trach on ventilator CMV mode 12/200/+5/30%, receiving albuterol; 9) 72-year-old male with COPD on HFNC 40 L/80% and BiPAP; 10) 57-year-old male with OSA, hypertension, stroke on CTC 28%; 11) 61-year-old female with respiratory failure on room air—include additional considerations and involved disciplines.
Is it appropriate to give fluoxetine (Prozac) 20 mg daily together with aripiprazole (Abilify) 5 mg daily for augmentation of depressive symptoms?
What activated partial thromboplastin time (aPTT) is considered acceptable for removal of a vascular sheath?
What is the appropriate management for a pregnant healthcare worker who sustains a dirty needle stick?
What is the recommended treatment for vaginal discharge syndrome, including empiric therapy for bacterial vaginosis, trichomoniasis, and Candida, and how should management be modified in pregnant patients?
On which day of a 28‑day cycle should micronized progesterone be started when using sequential hormone therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.